Copyright: Immunotech Applied Science Limited   京ICP备19008112号-1    
About
Overview
Team
History
Branch
Honor
Culture
Science and product
R & D Platform
Product Pipelines
Product introduction
Patient area
Past research
Patient recruitment
News
Company news
Industry news
Investor Relations
Prospectus
Financial Report
Announcements and Circulars
Corporate Governance
Investor Inquiry
Cooperation
Cooperation
Careers
Talent Strategy
Campus Recruiting
Social recruitment
Contact
Contact
Messages
Company News

Company News
Industry News

Industry News
EAL® WAS GRANTED BREAKTHROUGH THERAPY BY THE CENTER FOR DRUG EVALUATION

EAL® WAS GRANTED BREAKTHROUGH THERAPY BY THE CENTER FOR DRUG EVALUATION
2023-09-06
The first investigator meeting of Phase I Denocabtagene Ciloleucel Injection (Originally known as RC19D2) successfully held by Immunotech Biopharm Ltd

The first investigator meeting of Phase I Denocabtagene Ciloleucel Injection (Originally known as RC19D2) successfully held by Immunotech Biopharm Ltd
2023-07-24
SPECIAL TOPIC OF INNOVATIVE DRUGS: CAR-T CELL THERAPY | OVERVIEW OF MARKET AND PRODUCT DEVELOPMENT, R&D TREND AND COMMERCIALIZATION TREND

SPECIAL TOPIC OF INNOVATIVE DRUGS: CAR-T CELL THERAPY | OVERVIEW OF MARKET AND PRODUCT DEVELOPMENT, R&D TREND AND COMMERCIALIZATION TREND
2023-06-20
OBTAINED PHASE I CLINICAL TRIAL APPROVAL FOR DENOCABTAGENE CILOLEUCEL INJECTION (ORIGINALLY KNOWN AS RC19D2, CAR-T-D2, CAR-T-19-DNR)

OBTAINED PHASE I CLINICAL TRIAL APPROVAL FOR DENOCABTAGENE CILOLEUCEL INJECTION (ORIGINALLY KNOWN AS RC19D2, CAR-T-D2, CAR-T-19-DNR)
2023-06-09
CELL AND GENE THERAPY WILL BE THE KEY DEVELOPMENT DIRECTION OF BEIJING'S PHARMACEUTICAL AND HEALTH INDUSTRY

CELL AND GENE THERAPY WILL BE THE KEY DEVELOPMENT DIRECTION OF BEIJING'S PHARMACEUTICAL AND HEALTH INDUSTRY
2023-05-31
IMMUNOTECH BIOPHARM LTD DEBUTED AT THE ZHONGGUANCUN FORUM WITH EAL, AND CEO DR. WANG YU GAVE A WONDERFUL PRESENTATION AT THE 2023 ZHONGGUANCUN INTERNATIONAL TECHNOLOGY TRADING CONFERENCE

IMMUNOTECH BIOPHARM LTD DEBUTED AT THE ZHONGGUANCUN FORUM WITH EAL, AND CEO DR. WANG YU GAVE A WONDERFUL PRESENTATION AT THE 2023 ZHONGGUANCUN INTERNATIONAL TECHNOLOGY TRADING CONFERENCE
2023-05-31
TALKING ABOUT THE FRONTIERS OF CELL THERAPY INDUSTRY TOGETHER, STANDARDS EMPOWER SUSTAINABLE DEVELOPMENT OF ENTERPRISES

TALKING ABOUT THE FRONTIERS OF CELL THERAPY INDUSTRY TOGETHER, STANDARDS EMPOWER SUSTAINABLE DEVELOPMENT OF ENTERPRISES
2023-05-31
DISCUSSION ON THE KEY POINTS OF CMC RESEARCH IN VARIOUS STAGES OF INNOVATIVE DRUGS

DISCUSSION ON THE KEY POINTS OF CMC RESEARCH IN VARIOUS STAGES OF INNOVATIVE DRUGS
2023-05-26
SUMMARY | 46 GLOBALLY AVAILABLE GENE THERAPY DRUGS

SUMMARY | 46 GLOBALLY AVAILABLE GENE THERAPY DRUGS
2023-05-18
THE DEVELOPMENT MOMENTUM OF CELL THERAPY IN CHINA IS STRONG, WITH 14 APPROVED CLINICAL PRODUCTS AND 24 NEWLY ACCEPTED PRODUCTS IN THE FIRST QUARTER

THE DEVELOPMENT MOMENTUM OF CELL THERAPY IN CHINA IS STRONG, WITH 14 APPROVED CLINICAL PRODUCTS AND 24 NEWLY ACCEPTED PRODUCTS IN THE FIRST QUARTER
2023-05-10
Page up
1
2
...
7